Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

5 Stocks To Watch For April 9, 2018

SMIT, KANT, VYNE

Some of the stocks that may grab investor focus today are:

  • Wall Street expects Simulations Plus, Inc. (NASDAQ: SLP) to post quarterly earnings at $0.1 per share on revenue of $7.15 million after the closing bell. Simulations Plus shares gained 0.33 percent to close at $15.30 on Friday.
  • Schmitt Industries, Inc. (NASDAQ: SMIT) reported Q3 earnings of $0.00 per share, versus a year-ago loss of $0.04 per share. Its total sales rose 1.2 percent to $3.23 million. Schmitt Industries shares rose 2.62 percent to $2.60 in the after-hours trading session.
  • Proteostasis Therapeutics Inc (NASDAQ: PTI) disclosed that it has filed for a $100 million mixed shelf offering. Proteostasis Therapeutics shares declined 4.49 percent to $4.47 in the after-hours trading session.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • Deutsche Bank AG (USA) (NYSE: DB) named Christian Sewing as its new CEO. The bank’s new CEO announced plans to review investment banking business. Deutsche Bank shares fell 0.36 percent to $13.82 in the after-hours trading session.
  • Menlo Therapeutics Inc. (NASDAQ: MNLO) disclosed that its Phase 2 trial of serlopitant for pruritus associated with atopic dermatitis did not meet primary and key secondary efficacy endpoints. Menlo Therapeutics shares fell 2.76 percent to close at $35.22 on Friday.


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today